Wells Fargo analyst David Maris said the receipt of a Complete Response Letter from the FDA regarding Valeant's glaucoma product candidate, latanoprostene bunod, was unexpected, adding that if the manufacturing-related CRL is a sign of broader issues at a facility it could be serious for Valeant. In total, Maris views the three pipeline events recently reported by Valeant - which resulted in one approval, one rejection, and one recommendation for approval but with restrictions - as net negative, since he had expected approvals for all three. Maris keeps an Underperform rating on Valeant.